CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

Sabah Öney, President and Chief Executive Officer of Dispatch Bio joins Fred Hutch Board of Directors, bringing expertise in biotechnology leadership and innovation.

First-in-class Flare platform designed to address targeting and resistance mechanisms in solid tumors to expand curative potential of immunotherapies for cancer patients Platform based on convergence ...

Dispatch Bio Unveils First Clinical Program and Presents Data Supporting Flare Platform at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting DISP-10 is a novel tumor-specific virus and ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform, today announced two upcoming presentations at the Society for ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min This three-year-old company is ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform, today announced the appointment of Mauro Avanzi, M.D., Ph.D., as ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a ...

The MarketWatch News Department was not involved in the creation of this content. DISP-10 is a novel tumor-specific virus and CAR T combination designed to overcome key challenges of applying CAR T ...

CARsgen and Dispatch Bio ink clinical collaboration to evaluate flare platform and zevor-cel in solid tumours: Shanghai Wednesday, January 14, 2026, 18:00 Hrs [IST] CARsgen Therap ...